Neurodegeneration Exploring Commonalities Across Diseases: Workshop Summary (2013) / Chapter Skim
Currently Skimming:
Appendix C: Workshop Agenda
Appendix C: Workshop Agenda
Pages 79-90
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 79... ...
Recent findings have revealed potential commonalities and parallelisms in genetic and cellular mechanisms across neurodegenerative diseases. Enhanced sharing of research findings and collaboration across research communities could potentially help advance basic scientific knowledge about each disease and about neurodegeneration and neurodegenerative diseases in general.
|
From page 80... ...
Department of Veterans Affairs Session 1: Overview of common features across neurodegenerative diseases Session Objectives: The objectives of this session are to provide a genetic, clinical, and pathological framework to the notion that commonalities exist across neurodegenerative diseases. While this meeting focuses on discrete diagnostic entities, it is likely that this section may use examples from entities that cross these boundaries.
|
From page 81... ...
Ivinson Director, Harvard NeuroDiscovery Center Harvard Medical School 8:50 a.m. Discussion Among Speakers and Attendees Session 2: Protein aggregation in neurodegenerative diseases Session Objectives: The objectives of this session are to look at protein aggregation across the neurodegenerative diseases -- including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS, and frontotemporal dementia -- and • Highlight commonalities related to protein aggregation across these diseases, for example, autophagy.
|
From page 82... ...
9:10 a.m. Overview of Status of the Field and Session Objectives John Dunlop, Session Co-Chair Vice President, Discovery Neuroscience Innovative Medicine Unit AstraZeneca Lucie Bruijn, Session Co-Chair Chief Scientist ALS Association 9:20 a.m.
|
From page 83... ...
• Discuss opportunities for the development of mitochondria related biomarkers and therapeutic interventions. • Identify next steps that research sponsors, investigators, and others should take to facilitate collaborative research and drug development in this area, including frameworks for partnerships and collaboration.
|
From page 84... ...
Youle Senior Investigator National Institute of Neurological Disorders and Stroke 2:40 p.m. Discussion 2:55 p.m.
|
From page 85... ...
ADJOURN DAY ONE DAY TWO: May 1, 2012 8:00 a.m. Welcome and Objectives of Day Two Story Landis, Workshop Co-Chair Director National Institute of Neurological Disorders and Stroke John Trojanowski, Workshop Co-Chair Co-director, Center for Neurodegenerative Disease Research University of Pennsylvania session 4: neurodegenerative disease transmission and immune therapy Session Objectives: The objectives of this session are to • Provide an overview of the latest concepts on transmission of neurodegenerative diseases, including evidence that suggests that disease progression may occur through the cell-to-cell spread of pathological disease proteins.
|
From page 86... ...
Transmission of Prions and Alzheimer's Disease Abeta Amyloid Claudio Soto Professor of Neurology Director, Center for Alzheimer's Disease and Related Brain Disorders The University of Texas Medical School at Houston 8:35 a.m. Discussion Among Speakers and Attendees 8:50 a.m.
|
From page 87... ...
Discussion 11:45 a.m. LUNCH Session 5: errors in rna Session Objectives: The objectives of this session are to • Discuss how errors in RNA-binding proteins are causes of neurodegenerative diseases, including ALS, frontotemporal dementia, and spinal muscular atrophy, as well as triplet nucleotide expansion as a risk factor in disease (e.g., ataxin and ALS)
|
From page 88... ...
• Discuss yeast models to identify therapeutics and the emerging roles of non-coding RNA networks in the pathogenesis of neurodegenerative diseases. • Identify the next steps that research sponsors, investigators, and others should take to facilitate collaborative research and drug development in this area, including frameworks for partnerships and collaboration.
|
From page 89... ...
BREAK Session 6: future directions and next steps Session Objectives: A panel will synthesize and discuss key highlights from the workshop presentations and discussions, including • Identify key promising areas for future cross-disease research and collaboration. • Discuss opportunities for partnerships -- public–private and across disease-specific communities -- to advance neurodegeneration research and therapeutics development.
|
From page 90... ...
90 NEURODEGENERATION John Dunlop Vice President, Discovery Neuroscience Innovative Medicine Unit AstraZeneca Lucie Bruijn Chief Scientist ALS Association Lennart Mucke Director and Senior Investigator, Gladstone Institute of Neurological Disease Professor of Neurology and Neuroscience University of California, San Francisco Don Cleveland Professor and Chair, Department of Cellular and Molecular Medicine Head, Laboratory for Cell Biology Ludwig Institute for Cancer Research University of California, San Diego 3:30 p.m. Discussion Among Speakers and Attendees 4:30 p.m.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.